{"id":24176,"date":"2021-04-08T17:41:00","date_gmt":"2021-04-08T17:41:00","guid":{"rendered":"https:\/\/beonemedicines.ca\/fr\/?post_type=pressreleases&#038;p=24176"},"modified":"2025-12-05T15:08:49","modified_gmt":"2025-12-05T15:08:49","slug":"beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom","status":"publish","type":"pressreleases","link":"https:\/\/beonemedicines.ca\/fr\/pressreleases\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\/","title":{"rendered":"BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m"},"content":{"rendered":"<!-- Copy block -->\r\n<section class=\"nav-tertiary-sec copy-block  bg-white\" >\r\n    <div class=\"container\">\r\n        <div class=\"row\">\r\n            \r\n            <div class=\"col-md-8 col-lg-9\">\r\n                \r\n                <div class=\"main-container tab-container\">                    \r\n                                                <section class=\"section anim fadeInUp no-popup\">\r\n                            <!-- <section class=\"section anim fadeInUp no-popup\" > -->\r\n                                <div class=\"sec-header\">\r\n                                    <div class=\"sec-head\">\r\n                                                                                                                    <\/div>\r\n                                    <div class=\"sec-body\">\r\n                                                                                    \r\n                                            <div><p>Mississauga, Ont., \u2014 (BUSINESS WIRE) \u2014 Le 8 avril 2021 &#8212; BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), une soci\u00e9t\u00e9 de biotechnologie au stade commercial ax\u00e9e sur le d\u00e9veloppement et la commercialisation de m\u00e9dicaments novateurs dans le monde, a annonc\u00e9 aujourd\u2019hui le lancement officiel de BRUKINSA\u00ae (zanubrutinib) sur le march\u00e9 canadien pour le traitement des patients adultes atteints de macroglobulin\u00e9mie de Waldenstr\u00f6m (MW). La vente de BRUKINSA\u00ae (zanubrutinib) avait \u00e9t\u00e9 autoris\u00e9e par Sant\u00e9 Canada pour le traitement de cette maladie le 1 mars 2021 apr\u00e8s l\u2019obtention du statut d\u2019examen prioritaire en septembre 2020.<\/p>\n<\/div>\r\n                                                                            <\/div>\r\n                                    \r\n                                        <div class=\"sec-buttons\">\r\n                                            <a href=\"\/fr\/wp-content\/uploads\/sites\/4\/2025\/12\/BRUKINSA-Launch-in-Canada_CA-FR.pdf\" target=\"_blank\" class=\"btn-default btn-primary btn-download \">\r\n                                                <span>PDF<\/span>\r\n                                            <\/a>\r\n\r\n                                            \r\n                                        <\/div>\r\n                                    \r\n                                                                             <!-- <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px;\r\n                                             }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: ;\r\n                                            }\r\n                                         <\/style> -->\r\n                                                                             <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px; flex-wrap: wrap;\r\n                                            }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: 0 1 auto;\r\n                                            }\r\n\r\n                                            .after-buttons.multiple > div {\r\n                                                flex: 0 1 calc(50% - 30px);\r\n                                            }\r\n                                        <\/style>\r\n                                     \r\n                                    \r\n                                    <div class=\"after-buttons \">\r\n                                                                            <\/div>\r\n                                <\/div>\t\r\n                            <\/section>\r\n                                    <\/div>\r\n                \r\n            <\/div>\r\n            <div class=\"col-md-4 col-lg-3\">\r\n                \r\n            <\/div> \r\n        <\/div>\r\n    <\/div>\r\n<\/section>\r\n<!-- Copy block -->\r\n\n\n\n<p><\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"class_list":["post-24176","pressreleases","type-pressreleases","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m - BeOne Medicines FR<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m - BeOne Medicines FR\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beonemedicines.ca\/fr\/pressreleases\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\/\" \/>\n<meta property=\"og:site_name\" content=\"BeOne Medicines FR\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-05T15:08:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/pressreleases\\\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\\\/\",\"url\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/pressreleases\\\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\\\/\",\"name\":\"BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m - BeOne Medicines FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/#website\"},\"datePublished\":\"2021-04-08T17:41:00+00:00\",\"dateModified\":\"2025-12-05T15:08:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/pressreleases\\\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/pressreleases\\\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/pressreleases\\\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/\",\"name\":\"BeOne Medicines FR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/beonemedicines.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m - BeOne Medicines FR","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m - BeOne Medicines FR","og_url":"https:\/\/beonemedicines.ca\/fr\/pressreleases\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\/","og_site_name":"BeOne Medicines FR","article_modified_time":"2025-12-05T15:08:49+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/beonemedicines.ca\/fr\/pressreleases\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\/","url":"https:\/\/beonemedicines.ca\/fr\/pressreleases\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\/","name":"BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m - BeOne Medicines FR","isPartOf":{"@id":"https:\/\/beonemedicines.ca\/fr\/#website"},"datePublished":"2021-04-08T17:41:00+00:00","dateModified":"2025-12-05T15:08:49+00:00","breadcrumb":{"@id":"https:\/\/beonemedicines.ca\/fr\/pressreleases\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beonemedicines.ca\/fr\/pressreleases\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/beonemedicines.ca\/fr\/pressreleases\/beigene-met-en-marche-brukinsa-zanubrutinib-pour-le-traitement-de-la-macroglobulinemie-de-waldenstrom\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/beonemedicines.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"BeiGene met en march\u00e9 BRUKINSA\u00ae (zanubrutinib) pour le traitement de la macroglobulin\u00e9mie de Waldenstr\u00f6m"}]},{"@type":"WebSite","@id":"https:\/\/beonemedicines.ca\/fr\/#website","url":"https:\/\/beonemedicines.ca\/fr\/","name":"BeOne Medicines FR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beonemedicines.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/beonemedicines.ca\/fr\/wp-json\/wp\/v2\/pressreleases\/24176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedicines.ca\/fr\/wp-json\/wp\/v2\/pressreleases"}],"about":[{"href":"https:\/\/beonemedicines.ca\/fr\/wp-json\/wp\/v2\/types\/pressreleases"}],"wp:attachment":[{"href":"https:\/\/beonemedicines.ca\/fr\/wp-json\/wp\/v2\/media?parent=24176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}